An announcement from GlucoTrack ( (GCTK) ) is now available.
GlucoTrack reported its financial results for 2024, highlighting a transformative year as it moved from a preclinical to a clinical stage company. The company strengthened its leadership team and secured significant funding to support its growth and clinical development. Key achievements included the successful completion of the first human clinical study of its CBGM technology and obtaining ISO certification, positioning the company for further advancements in 2025. Despite increased expenses leading to a higher net loss, GlucoTrack’s financial position was bolstered by multiple funding rounds, providing a runway for upcoming milestones.
More about GlucoTrack
GlucoTrack, Inc. is a medical technology company focused on the design, development, and commercialization of innovative technologies for diabetes management. The company is advancing its continuous blood glucose monitoring (CBGM) technology, aiming to offer a fully implantable system with real-time measuring capabilities.
YTD Price Performance: -97.25%
Average Trading Volume: 6,453,157
Technical Sentiment Signal: Buy
Current Market Cap: $2.13M
See more insights into GCTK stock on TipRanks’ Stock Analysis page.